| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
27 |
| Employees |
85 |
| Revenues (TTM) (Millions $) |
129 |
| Net Income (TTM) (Millions $) |
-59 |
| Cash Flow (TTM) (Millions $) |
134 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Calliditas Therapeutics Ab is a biopharmaceutical company focused on developing and commercializing therapies for patients with orphan diseases in the liver and kidney. Calliditas was founded in 2004 and is headquartered in Stockholm, Sweden. The company is publicly traded on the NASDAQ Stockholm exchange under the ticker symbol CALTX.
Calliditase lead product candidate is Nefecon, a proprietary formulation of budesonide that is being developed as a treatment for IgA nephropathy (IgAN). IgAN is a progressive kidney disease characterized by inflammation and damage to the glomeruli, which leads to declining kidney function over time. There are currently no approved therapies for IgAN, and the disease affects an estimated 10-15% of the global population with chronic kidney disease. Nefecon works by targeting the immune system and reducing inflammation in the kidneys, which has the potential to slow or halt the progression of the disease.
In addition to Nefecon, Calliditas also has a pipeline of other product candidates in development. The company is currently exploring the use of Nefecon in other kidney diseases, as well as developing a therapy for primary biliary cholangitis (PBC), a rare, progressive liver disease. Calliditas is also exploring the use of a novel technology platform called KAND567, which has the potential to treat several types of liver and kidney diseases by targeting the molecular pathways involved in fibrosis, inflammation, and cellular damage.
Calliditas has a team of experienced executives and advisors with a strong track record of success in the biopharmaceutical industry. The companyes management team includes CEO Ren'e Aguiar-Lucander, who has over 25 years of experience in the life sciences industry; CMO Jens Kristensen, who previously served as the CMO of Acorda Therapeutics and has over 20 years of experience in drug development; and CFO Fredrik Johansson, who has extensive experience in finance and strategy for biotech companies.
Overall, Calliditas is a promising biopharmaceutical company with a strong focus on developing and commercializing therapies for patients with orphan diseases in the liver and kidney. With its lead product candidate Nefecon in late-stage clinical development and a pipeline of other promising therapies, Calliditas has the potential to become a significant player in the rare disease space.
Company Address: Kungsbron 1, D5 Stockholm 111
Company Phone Number: 8 411 3005 Stock Exchange / Ticker: NASDAQ CALT
|
%
0.25% 